Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 2
Submit an article Journal homepage
130
Views
3
CrossRef citations to date
0
Altmetric
Theme: Sarcoma - Case Report

The coexistence of clear cell renal cell carcinoma and gastrointestinal stromal tumor with portal vein metastasis, and its favorable response to sunitinib

Jin Tao Department of Urology, West China Hospital, Sichuan University, Sichuan, China; Department of Urology, West China Hospital, Sichuan University, Sichuan, China
,
Chen Ni Department of Pathology, West China Hospital, Sichuan University, Sichuan, China; Department of Pathology, West China Hospital, Sichuan University, Sichuan, China
,
Yao Jin Department of Radiology, West China Hospital, Sichuan University, Sichuan, China; Department of Radiology, West China Hospital, Sichuan University, Sichuan, China
,
Zhu Yuchun Department of Urology, West China Hospital, Sichuan University, Sichuan, China; Department of Urology, West China Hospital, Sichuan University, Sichuan, China
,
Zhang Peng Department of Urology, West China Hospital, Sichuan University, Sichuan, China; Department of Urology, West China Hospital, Sichuan University, Sichuan, China
,
Yang Yuru Department of Urology, West China Hospital, Sichuan University, Sichuan, China; Department of Urology, West China Hospital, Sichuan University, Sichuan, China
&
Zeng Hao Department of Urology, West China Hospital, Sichuan University, Sichuan, China; Department of Urology, West China Hospital, Sichuan University, Sichuan, China. [email protected]
 show all
Pages 131-136 | Published online: 10 Jan 2014

References

  • Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA. Cancer J. Clin. 61(4), 212–236 (2011).
  • Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 22(3), 454–463 (2004).
  • Feng F, Liu XH, Xie Q, Liu WQ, Bai CG, Ma DL. Expression and mutation of c-kit gene in gastrointestinal stromal tumors. World J. Gastroenterol. 9(11), 2548–2551 (2003).
  • Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol. 33(5), 459–465 (2002).
  • Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum. Pathol. 33(5), 466–477 (2002).
  • Buchdunger E, Cioffi CL, Law N et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295(1), 139–145 (2000).
  • Blanke CD, Corless CL. State-of-the art therapy for gastrointestinal stromal tumors. Cancer Invest. 23(3), 274–280 (2005).
  • Van Glabbeke M, Verweij J, Casali PG et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer – Italian Sarcoma Group – Australasian Gastrointestinal Trials Group study. J. Clin. Oncol. 23(24), 5795–5804 (2005).
  • Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440), 1127–1134 (2004).
  • Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9(1), 327–337 (2003).
  • Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544), 1329–1338 (2006).
  • Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon-α in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(22), 3584–3590 (2009).
  • Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon-α in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115–124 (2007).
  • Au WY, Ho KM, Shek TW. Papillary renal cell carcinoma and gastrointestinal stromal tumor: a unique association. Ann. Oncol. 15(5), 843–844 (2004).
  • Resorlu B, Baltaci S, Resorlu M, Kankaya D, Savas B. Coexistence of papillary renal cell carcinoma and gastrointestinal stromal tumor in a case. Turk. J. Gastroenterol. 18(1), 47–49 (2007).
  • Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21(23), 4342–4349 (2003).
  • Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607), 708–710 (2003).
  • Debiec-Rychter M, Sciot R, Le Cesne A et al.; EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian Gastrointestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer 42(8), 1093–1103 (2006).
  • Latif F, Tory K, Gnarra J et al. Identification of the von Hippel–Lindau disease tumor suppressor gene. Science 260(5112), 1317–1320 (1993).
  • Schmidt L, Duh FM, Chen F et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16(1), 68–73 (1997).
  • Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin. Diagn. Pathol. 23(2), 70–83 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.